Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 21, 2013
Woodcliff Lake, NJ and Montreal, Quebec, February 21, 2013 - Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX)...
-
Feb 14, 2013
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational drug...
-
Jan 10, 2013
Morphotek(®) Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent...
-
Dec 19, 2012- Companies Pledge to Make Results Publicly Accessible in an Effort to Accelerate Cancer Drug Development -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, announced today that it has...
-
Dec 17, 2012
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset...